ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results for the fourth quarter and full year ended December 31, 2019.
March 18, 2020
· 17 min read